<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577693</url>
  </required_header>
  <id_info>
    <org_study_id>115148</org_study_id>
    <nct_id>NCT01577693</nct_id>
  </id_info>
  <brief_title>Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects</brief_title>
  <acronym>ARI115148</acronym>
  <official_title>An Open-label, Single Dose, Randomized, Two-period Crossover Study to Investigate the Bioavailability of a Novel Dosage Form of Dutasteride in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the bioavailability of 0.5mg dutasteride novel
      formulation compared to the currently marketed 0.5mg dutasteride soft gel capsule in fasted
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the bioavailability of 0.5mg dutasteride in a novel
      formulation compared to the currently marketed 0.5mg dutasteride soft gel capsule in fasted
      healthy male subjects. This will be an open-label, single dose, randomized, two-period
      crossover study in healthy male subjects. Subjects will receive a single oral dose 0.5mg
      novel dutasteride formulation and a single oral dose 0.5mg dutasteride soft gel capsule in a
      fasted state. Each dose of the study medication will be separated by a 28-day washout period.
      Blood samples for pharmacokinetic analysis will be taken at regular intervals after dosing.
      Safety will be assessed by measurement of blood pressure, heart rate, laboratory data, and
      review of adverse events. The study will enrol approximately 35 healthy male subjects to
      ensure that 30 subjects complete the study. The study will be conducted in the USA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2011</start_date>
  <completion_date type="Actual">August 31, 2011</completion_date>
  <primary_completion_date type="Actual">August 31, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>Change from Day 1 (session 1) compared to Day 29 (session 2), predose, .25, .5, .75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72</time_frame>
    <description>To assess the dutasteride relative bioavailability of the of 0.5 mg novel formulation compared with the currently marketed 0.5 mg soft gelatin capsule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Changes from screening to 3 months</time_frame>
    <description>Changes in blood pressure and pulse rates, review of number of subjects with adverse events, and changes in clinical laboratory data.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>0.5 mg novel dose form (test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg novel dose form (test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg Soft Gel Capsule</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0.5 mg Soft Gel Capsule (reference)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutasteride</intervention_name>
    <description>novel dutasteride</description>
    <arm_group_label>0.5 mg novel dose form (test)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutasteride</intervention_name>
    <description>dutasteride soft gel capsule</description>
    <arm_group_label>0.5 mg Soft Gel Capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible and experienced physician.

          -  Males between 20 and 45 years of age inclusive, at the time of signing the informed
             consent form.

          -  Male subjects with female partners of child-bearing potential must agree to use one of
             the contraception.

          -  Body mass index within the range 18-30 kg/m2 (inclusive); weight range 55-95 kg
             (inclusive).

          -  Capable of giving written informed consent.

          -  Single QTcB &lt; 450 msec.

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline
             phosphatase, and bilirubin less than or equal to 1.5xULN (isolated bilirubin &gt;1.5xULN
             is acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).

        Exclusion Criteria:

          -  History of postural hypotension, dizziness, poor hydration, vertigo, vaso-vagal
             reactions or any other signs and symptoms of orthostasis.

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  Subject is mentally or legally incapacitated.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements.

          -  History of sensitivity to dutasteride, components thereof or drugs of this class or a
             history of drug or other allergy.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia

          -  The subject has participated in a clinical trial for 30 days, 5 half-lives or twice
             the duration of the biological effect of the investigational product (whichever is
             longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  A positive pre-study drug/alcohol screen.

          -  History of regular alcohol consumption.

          -  Consumption of red wine, grapefruit juice, grapefruit and related hybrids, and jufen
             grapes.

          -  The subject has donated blood or blood products in excess of 500 mL within a 56 day
             period.

          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or
             nicotine-containing products within 6 months.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/115148?search=study&amp;search_terms=115148#rs</url>
    <description>Results for study 115148 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2012</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dutasteride</keyword>
  <keyword>cross over study</keyword>
  <keyword>bioavailability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115148</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115148</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115148</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115148</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115148</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115148</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115148</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

